G1 Therapeutics Inc Stock News

Goldman Sachs Group Inc. decreased its holdings in G1 Therapeutics Inc (NASDAQ:GTHX) by 32.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Ex

G1 Therapeutics Inc (NASDAQ:GTHX) shares fell 5.3% during trading on Tuesday . The stock traded as low as $10.55 and last traded at $10.61, 635,212 shares were traded during mid-day trading. An increa

G1 Therapeutics (NASDAQ:GTHX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, Zacks.com reports. The brokerage curr

RESEARCH TRIANGLE PARK, N.C., April 07, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.

Credit Suisse AG lifted its position in shares of G1 Therapeutics Inc (NASDAQ:GTHX) by 12.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission.

G1 Therapeutics (NASDAQ:GTHX) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Friday, BidAskClub reports. Several

G1 Therapeutics Inc (NASDAQ:GTHX) rose 5.4% during mid-day trading on Monday . The stock traded as high as $11.96 and last traded at $11.95, approximately 240,738 shares traded hands during mid-day tr

NextCure appoints Garry Nicholson to board of directors NXTC GTHX

NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today

G1 Therapeutics Inc (NASDAQ:GTHX) traded up 5.8% on Tuesday . The stock traded as high as $11.51 and last traded at $11.29, 337,984 shares traded hands during trading. An increase of 10% from the aver

Bank of Montreal Can lifted its position in shares of G1 Therapeutics Inc (NASDAQ:GTHX) by 43.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exch

Citigroup Inc. lowered its position in shares of G1 Therapeutics Inc (NASDAQ:GTHX) by 54.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange

G1 Therapeutics (NASDAQ:GTHX) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Tuesday, BidAskClub reports. Other equities research

ProShare Advisors LLC reduced its position in shares of G1 Therapeutics Inc (NASDAQ:GTHX) by 9.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exc

Shares of G1 Therapeutics Inc (NASDAQ:GTHX) have been assigned a consensus rating of “Buy” from the ten brokerages that are presently covering the company, MarketBeat reports. One equities researc